🏛️ Verified NIH Record • Updated 2025-03-13
Study to Evaluate D-1553 in Subjects With Solid Tumors (NCT04585035)
A Phase 1/2, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors With KRasG12C Mutation
🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: InventisBio Co., Ltd
🩺 Plain-English Summary (8th-Grade Level)
This is a phase 1/2, open label study of D-1553 single agent and combination treatment to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic solid tumor with KRasG12C mutation.
Who can join: Review the eligibility criteria below.
Location: Research Site — Fresno, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (25 Sites)
- Research Site — Fresno, California
- Research Site — Orange, California
- Research Site — San Francisco, California
- Research Site — Louisville, Kentucky
- Research Site — Detroit, Michigan
- Research Site — New York, New York
- Research Site — Portland, Oregon
- Research Site — Blacktown, New South Wales
- Research Site — East Albury, New South Wales
- Research Site — Kogarah, New South Wales
- Research Site — Waratah, New South Wales
- Research Site — Woodville South, South Australia
- Research Site — Fitzroy, Victoria
- Research Site — Frankston, Victoria
- Research Site — Malvern, Victoria
- Research Site — Nedlands, Western Australia
- Research Site — Seogu, Busan
- Research Site — Seongnam-si, Gyeonggi-do
- Research Site — Seoul,
- Research Site — Seoul,
- Research Site — Seoul,
- Research Site — Tainan,
- Research Site — Taipei,
- Research Site — Taipei,
- Research Site — Taoyuan City,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumor, Adult
- A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody — Sarasota, Florida
- First-in-Human Study of ICT01 in Patients With Advanced Cancer — Gilbert, Arizona
- A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors — Los Angeles, California
- Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab — Los Angeles, California
- A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial — Scottsdale, Arizona
- A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression — Gilbert, Arizona
Explore by condition: All Solid Tumor, Adult clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.